pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,462 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT776Endpoints580BioPharma Dive223onclive165Fierce Biotech54BioSpace52raps24
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • FDA says Zyn can market its pouches as safer than cigarettes
    The influence of the alcohol industry on policy, AI Claude for scientists, and more health news from Morning Rounds
    STAT · 25d ago↗ source
  • STAT+: FDA approves Orca Bio’s T cell therapy for blood cancer patients
    The FDA approved a T-cell therapy from Orca Bio that reduces the risk of a debilitating immune reaction in patients with blood cancers undergoing stem cell transplants.
    STAT · 25d ago↗ source
  • Ipsen to scoop up Memo Therapeutics and its kidney infection drug
    Ipsen is on an M&A roll. The French drugmaker announced its second deal of the week, saying it would buy Memo Therapeutics and its drug candidate called potravitug for a viral ...
    Endpoints
← prev
page 21 of 59
next →
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
· 25d ago
↗ source
  • A June flourish lifts biotech megaround tally in first half of 2026
    Forty private biotech companies disclosed funding rounds of $100 million or more in the first half of 2026, according to an Endpoints News tally. That's more than the same period of 2025 ...
    Endpoints · 25d ago↗ source
  • STAT+: Booze schmooze: The alcohol industry, frazzled by headwinds, wields its power behind the scenes
    Demand for alcohol is declining. The industry is fighting harder and more creatively than ever against limits — and winning.
    STAT · 25d ago↗ source
  • STAT+: The biotech scorecard for the third quarter: 15 stock-moving events to watch
    Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter.
    STAT · 25d ago↗ source
  • Opinion: Maryland Gov. Wes Moore: How to improve young men’s mental health
    “We need to stop treating our young men and boys as problems to be solved, and start treating them as people to be invested in,” writes Gov. Wes Moore.
    STAT · 25d ago↗ source
  • Opinion: What Ebola and Marburg are teaching us about the next pandemic
    “What is urgently needed is a shift from pathogen-specific diagnostics toward pathogen-agnostic diagnostic systems,” write Krutika Kuppalli and Placide Mbala.
    STAT · 25d ago↗ source
  • STAT+: AI company Anthropic announces it will begin developing drugs of its own
    AI giant Anthropic has already become a dominant player in technology and a household name for everyday users of artificial intelligence. Can it make drugs too?
    STAT · 25d ago↗ source
  • Republican Tom Kean Jr. reveals depression diagnosis after his four-month absence from Congress
    Depression, the New Jersey congressman said, “is physical, it is emotional, and until you experience it yourself, it is difficult to fully understand how powerful this illness can be.”
    STAT · 25d ago↗ source
  • FDA reviewers oppose allowing seven peptides for compounding
    Ahead of an FDA advisory committee meeting to discuss lifting restrictions on seven popular peptides, agency reviewers have recommended against including the peptides on a list of bulk drug substan…
    Endpoints · 26d ago↗ source
  • Anthropic debuts Claude Science, an AI product for bioscience
    Anthropic upended software programming with the runaway success of the coding agent Claude Code. For its next act, the AI lab is turning its attention to biopharma. On Tuesday, Anthropic announce…
    Endpoints · 26d ago↗ source
  • Eli Lilly, Fujifilm among seven selected for FDA’s PreCheck pilot
    The FDA has chosen the first seven companies to participate in its PreCheck pilot program, a group that includes large drugmakers Eli Lilly and Regeneron as well as manufacturers Cellares and Fujif…
    Endpoints · 26d ago↗ source
  • STAT+: Anthropic releases Claude Science, a product aimed at researchers, the pharma industry
    Anthropic released Claude Science, an application that optimizes its large language model for scientists and, especially, those doing research at pharma companies.
    STAT · 26d ago↗ source
  • AbbVie and Genmab's latest win brings Epkinly closer to label expansion
    AbbVie and Genmab’s bispecific antibody Epkinly succeeded in combination with a widely used cancer drug, bringing it one step closer to a potential label expansion in diffuse large B cell lymphoma.…
    Endpoints · 26d ago↗ source
  • Marburg outbreak is reported in Uganda, threatening to complicate Ebola response in region
    Sources confirm to STAT that Marburg cases have been detected in western Uganda, adding another viral hemorrhagic fever outbreak in central Africa.
    STAT · 26d ago↗ source
  • Abivax aims to set cancer concerns with ulcerative colitis drug to rest
    Late on Monday, Abivax released new trial data on its ulcerative colitis candidate, showing that cancer cases in a Phase 3 trial were within the expected range for these patients. The company says…
    Endpoints · 26d ago↗ source
  • Health AI caution crosses into confidence
    How people in health tech feel about AI in healthcare has changed drastically from just a year ago. Each year, health tech venture firm Venrock partners Bob Kocher, Bryan Roberts and Siobhan Nola…
    Endpoints · 26d ago↗ source
  • FDA's acting director of cell and gene therapies to leave position
    Vijay Kumar is leaving his role as acting director of CBER's Office of Therapeutic Products and will soon consider options both inside and outside the FDA, he told Endpoints News on Tuesday. Kuma…
    Endpoints · 26d ago↗ source
  • Sarepta's FDA decision date; Flare gets Anna Protopapas as CEO
    Plus news about Deerfield, InflaRx, Praxis, Nuvectis, Pyxis Oncology, Vistagen, Arcutis Biotherapeutics and Nxera. 🔎 FDA to decide on future of Sarepta exon-skipping drugs by end of February: Th…
    Endpoints · 26d ago↗ source
  • STAT+: All of Us tests a new approach to collect real-world data for research
    The NIH All of Us Research Program has secured thousands of electronic medical records through an innovative use of patient data-sharing networks
    STAT · 26d ago↗ source
  • STAT+: Investors double down on Bain-backed startup
    FDA's top gene therapy regulator steps down, Trump's plan to lower GLP-1 prices, and more biotech news
    STAT · 26d ago↗ source
  • STAT+: FDA digital leader hints at coming AI policy updates
    Today's health tech news includes virtual PT for a whole country, what the FDA is considering on AI policy, and more
    STAT · 26d ago↗ source
  • STAT+: Pharmalittle: We’re reading about Chinese trial sites being probed, RFK Jr. and peptides, and more
    U.S. lawmakers are investigating whether several large drugmakers have been involved ​in clinical trials in China that helped fuel its military capability
    STAT · 26d ago↗ source
  • Nominations are open for the 2026 Endpoints 11 awards
    There’s never been a higher bar for innovation than right now. Almost any promising molecule quickly has a horde of copycats. Development costs keep rising. Investors are leaning on seemingly saf…
    Endpoints · 26d ago↗ source